SHP2 inhibition and adjuvant therapy synergistically target KIT‐mutant GISTs via ERK1/2‐regulated GSK3β/cyclin D1 pathway
SHP2 plays a pivotal role as a signal transducer in the MAPK/ERK signaling pathway. SHP2 controls the cell cycle via the GSK3β/cyclin D1/Rb pathway in oncogenic KIT-driven GIST. Inhibition of SHP2 synergizes with adjuvant therapy drugs in inhibiting KIT-driven GIST with primary and secondary mutations both in vitro and in vivo.
Authors
- Xi Xiang (ORCID: https://orcid.org/0000-0002-5590-7289)
- Lei Huang (ORCID: https://orcid.org/0000-0002-2475-5518)
- Shaohua Yang (ORCID: https://orcid.org/0000-0003-4000-1748)
- Shuang Mao
- Yulong He (ORCID: https://orcid.org/0000-0002-1902-0963)
- Xinhua Zhang
- Mingzhe Li (ORCID: https://orcid.org/0000-0002-3913-3797)
- Jiaying Yu (ORCID: https://orcid.org/0009-0003-7777-2287)
- Xianming Jiang
- Chunxiao He
Institutions
- Sun Yat-sen University (CN)
- The Seventh Affiliated Hospital of Sun Yat-sen University (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
Publication Details
- Journal
- Clinical and Translational Medicine
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1002/ctm2.70231
- Citations
- 3
- Primary Topic
- Gastrointestinal Tumor Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 5.43